Drugs & Therapy Perspectives

, Volume 18, Issue 1, pp 17–20 | Cite as

Postexposure prophylaxis for occupational exposure to HIV has its risks

Drug Reactions and Interactions
  • 10 Downloads

Keywords

Lamivudine Zidovudine Healthcare Worker Therapeutic Drug Monitoring Nevirapine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lee LM, Henderson DK. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf 2001; 24(8): 587–97PubMedCrossRefGoogle Scholar
  2. 2.
    Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001; 50(RR11); 1–42Google Scholar
  3. 3.
    Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331(18): 1173–80PubMedCrossRefGoogle Scholar
  4. 4.
    Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337(21): 1485–90PubMedCrossRefGoogle Scholar
  5. 5.
    Fahrner R, Beekmann SE, Nelson L, et al. Combination post-exposure prophylaxis (PEP): a prospective study of HIV-exposed health care workers (HCW). 12th International Conference on AIDS; 1998 Jun 28–Jul 3; GenevaGoogle Scholar
  6. 6.
    Swotinsky RB, Steger KA, Sulis C, et al. Occupational exposure to HIV: experience at a tertiary care center. J Occup Environ Med 1998; 40(12): 1102–9PubMedGoogle Scholar
  7. 7.
    Blanche S, Rouzioux C, Mandelbrot L, et al. Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission. 6th Annual Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31–Feb 4; ChicagoGoogle Scholar
  8. 8.
    Smyth AC. Important drug warning. Bristol-Myers Squibb Company. Available at: http://www.fda.gov/medwatch/safety/2001/pregwarnfinalbms.pdf [Accessed 2001 Mar 12]
  9. 9.
    British National Formulary. No. 41. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2001 MarGoogle Scholar
  10. 10.
    D’Silva M, Leibowitz D, Flaherty JP. Seizure associated with zidovudine. Lancet 1995; 346(8972): 452PubMedCrossRefGoogle Scholar
  11. 11.
    Henry K, Acosta EP, Jochimsen E. Hepatoxicity and rash associated with zidovudine and zalcitabine chemoprophyIaxis. Ann Intern Med 1996; 124(9): 855PubMedGoogle Scholar
  12. 12.
    Wang SA, Puro V. Toxicity of post-exposure prophylaxis for human immunodeficiency virus. In: Panlilio L, editor. Balliere’s Clin Infect Dis. Vol 5. London: Balliere-Tindall, Inc, 1999: 349–63Google Scholar
  13. 13.
    Spenatto N, Viraben R. Early lipodystrophy occurring during postexposure prophylaxis. Sex Transm Infect 1998; 74(6): 455PubMedGoogle Scholar
  14. 14.
    Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA 2000 Dec; 284(21): 2723PubMedGoogle Scholar
  15. 15.
    Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures — worldwide, 1997–2000. MMWR 2001; 49(51): 1153–6Google Scholar
  16. 16.
    Bangsberg D, Goldschmidt RH. Postexposure prophylaxis for occupational exposure to HIV. JAMA 1999; 282(17): 1623–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations